<!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pharma Daily Brief | PiercePharma 朝刊</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Sans+JP:wght@400;500;600;700&family=IBM+Plex+Sans:wght@400;500;600&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-main: #0f1419;
      --bg-card: #1a2332;
      --bg-card-hover: #232f42;
      --text-primary: #e8edf4;
      --text-secondary: #94a3b8;
      --text-muted: #64748b;
      --accent-pipeline: #38bdf8;
      --accent-regulatory: #fb923c;
      --accent-deals: #4ade80;
      --accent-earnings: #a78bfa;
      --border: #2d3a4f;
      --link: #7dd3fc;
      --link-hover: #bae6fd;
    }
    * { box-sizing: border-box; margin: 0; padding: 0; }
    body { font-family: 'IBM Plex Sans', 'Noto Sans JP', sans-serif; background: var(--bg-main); color: var(--text-primary); line-height: 1.6; min-height: 100vh; padding: 24px 16px; }
    .container { max-width: 720px; margin: 0 auto; }
    .header { margin-bottom: 32px; padding-bottom: 20px; border-bottom: 1px solid var(--border); }
    .header h1 { font-size: 1.5rem; font-weight: 700; letter-spacing: -0.02em; }
    .header .date { font-size: 0.875rem; color: var(--text-muted); margin-top: 4px; font-weight: 500; }
    .header .subtitle { font-size: 0.8125rem; color: var(--text-secondary); margin-top: 8px; }
    .header .scope { font-size: 0.75rem; color: var(--text-muted); margin-top: 12px; padding: 10px 12px; background: var(--bg-card); border-radius: 6px; border: 1px solid var(--border); line-height: 1.5; }
    .header .scope strong { color: var(--text-secondary); }
    .category-section { margin-bottom: 28px; }
    .category-header { display: flex; align-items: center; gap: 8px; margin-bottom: 12px; font-size: 0.8125rem; font-weight: 600; text-transform: uppercase; letter-spacing: 0.05em; }
    .category-header .badge { width: 8px; height: 8px; border-radius: 50%; }
    .category-pipeline .badge { background: var(--accent-pipeline); } .category-pipeline .category-header { color: var(--accent-pipeline); }
    .category-regulatory .badge { background: var(--accent-regulatory); } .category-regulatory .category-header { color: var(--accent-regulatory); }
    .category-deals .badge { background: var(--accent-deals); } .category-deals .category-header { color: var(--accent-deals); }
    .category-earnings .badge { background: var(--accent-earnings); } .category-earnings .category-header { color: var(--accent-earnings); }
    .article-card { background: var(--bg-card); border: 1px solid var(--border); border-left: 3px solid; border-radius: 8px; padding: 16px; margin-bottom: 12px; transition: background 0.2s; }
    .article-card:hover { background: var(--bg-card-hover); }
    .article-card.pipeline { border-left-color: var(--accent-pipeline); }
    .article-card.regulatory { border-left-color: var(--accent-regulatory); }
    .article-card.deals { border-left-color: var(--accent-deals); }
    .article-card.earnings { border-left-color: var(--accent-earnings); }
    .article-card .title { font-size: 1rem; font-weight: 600; margin-bottom: 8px; line-height: 1.4; }
    .article-card .title a { color: var(--text-primary); text-decoration: none; transition: color 0.2s; }
    .article-card .title a:hover { color: var(--link-hover); }
    .article-card .summary { font-size: 0.875rem; color: var(--text-secondary); margin-bottom: 10px; line-height: 1.5; }
    .article-card .meta { display: flex; flex-wrap: wrap; gap: 12px; font-size: 0.75rem; color: var(--text-muted); }
    .article-card .meta span { display: inline-flex; align-items: center; gap: 4px; }
    .article-card .link-wrap { margin-top: 10px; }
    .article-card .link-wrap a { font-size: 0.8125rem; color: var(--link); text-decoration: none; transition: color 0.2s; }
    .article-card .link-wrap a:hover { color: var(--link-hover); text-decoration: underline; }
    .article-card .link-wrap a::after { content: '→'; }
    .importance { display: inline-flex; gap: 2px; }
    .importance .star { color: var(--accent-regulatory); font-size: 0.7rem; }
    .importance .star.empty { color: var(--text-muted); opacity: 0.5; }
    .article-card .meta .region { font-size: 0.7rem; padding: 2px 6px; border-radius: 4px; font-weight: 500; }
    .region-us { background: rgba(56,189,248,0.2); color: var(--accent-pipeline); }
    .region-europe { background: rgba(251,146,60,0.2); color: var(--accent-regulatory); }
    .region-china { background: rgba(74,222,128,0.2); color: var(--accent-deals); }
    @media (max-width: 480px) { body { padding: 16px 12px; } .header h1 { font-size: 1.25rem; } .article-card { padding: 14px; } }
  </style>
</head>
<body>
  <div class="container">
    <header class="header">
      <h1>Pharma Daily Brief</h1>
      <div class="date">2026年02月24日（火）</div>
      <div class="subtitle">パイプライン・規制・M&A・決算｜医薬・バイオ業界の重要ニュース（毎朝更新）</div>
      <div class="scope">
        <strong>対象地域：</strong>約9割は米国。欧州はノボノルディスク、ブリストルマイヤーズスクイーブ、サノフィ、ロッシュ、バイエルなど大手の重要ニュースを追加。中国は個別企業より<strong>医薬品規制当局の動向</strong>（変化が大きい場合）を掲載。
      </div>
    </header>


    <section class="category-section category-pipeline">
      <h2 class="category-header">
        <span class="badge"></span>
        Pipeline
      </h2>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/novo-knock-down-ozempic-wegovy-list-prices-27-self-pay-channels-unaffected" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/novo-knock-down-ozempic-wegovy-list-prices-27-self-pay-channels-unaffected&quot; hreflang=&quot;en&quot;&gt;Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected&lt;/a&gt;</a></h3>
        <p class="summary">Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/novo-knock-down-ozempic-wegovy-list-prices-27-self-pay-channels-unaffected" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/biomarin-officially-pulls-plug-hemophilia-gene-therapy-roctavian-taking-119m-write-after" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/biomarin-officially-pulls-plug-hemophilia-gene-therapy-roctavian-taking-119m-write-after&quot; hreflang=&quot;en&quot;&gt;BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder&lt;/a&gt;</a></h3>
        <p class="summary">Just three months after further scaling back its support for the struggling hemophilia A gene therapy Roctavian, the company is walking away altogether by pulling the treatment from the market.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/biomarin-officially-pulls-plug-hemophilia-gene-therapy-roctavian-taking-119m-write-after" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/astrazeneca-ceo-pay-hits-239m-amid-significant-geopolitical-uncertainty-2025" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/astrazeneca-ceo-pay-hits-239m-amid-significant-geopolitical-uncertainty-2025&quot; hreflang=&quot;en&quot;&gt;AstraZeneca CEO pay hits $23.9M amid ‘significant geopolitical uncertainty’ in 2025&lt;/a&gt;</a></h3>
        <p class="summary">AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty” to advance the British pharma toward an ambitious 2030 goal.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/astrazeneca-ceo-pay-hits-239m-amid-significant-geopolitical-uncertainty-2025" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/indivior-picks-havas-lead-us-marketing-efforts-dtc-push-ramps" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/indivior-picks-havas-lead-us-marketing-efforts-dtc-push-ramps&quot; hreflang=&quot;en&quot;&gt;Indivior picks Havas to lead US marketing efforts as DTC push ramps up&lt;/a&gt;</a></h3>
        <p class="summary">Havas will lead Indivior’s integrated strategy, creative, media and digital efforts across healthcare professional and direct-to-consumer audiences.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/indivior-picks-havas-lead-us-marketing-efforts-dtc-push-ramps" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/amid-obesity-push-pfizer-strikes-deal-worth-495m-market-sciwinds-approved-glp-1-china" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/amid-obesity-push-pfizer-strikes-deal-worth-495m-market-sciwinds-approved-glp-1-china&quot; hreflang=&quot;en&quot;&gt;Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind&#x27;s approved GLP-1 in China&lt;/a&gt;</a></h3>
        <p class="summary">Looking to gain an edge as its broader obesity ambitions take shape, Pfizer has picked up the rights to a recently approved GLP-1 in China, unlocking an immediate commercial opportunity in type 2 diab…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/amid-obesity-push-pfizer-strikes-deal-worth-495m-market-sciwinds-approved-glp-1-china" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/novartis-settles-18-month-old-lawsuit-estate-baltimore-woman-whose-cells-were-extracted-75" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/novartis-settles-18-month-old-lawsuit-estate-baltimore-woman-whose-cells-were-extracted-75&quot; hreflang=&quot;en&quot;&gt;Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago&lt;/a&gt;</a></h3>
        <p class="summary">The family of a Baltimore woman whose cells were extracted for medical research without her consent 75 years ago has settled a lawsuit with Novartis, with terms of the agreement confidential. Lawsuits…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/novartis-settles-18-month-old-lawsuit-estate-baltimore-woman-whose-cells-were-extracted-75" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026&quot; hreflang=&quot;en&quot;&gt;Regulatory tracker: Sanofi, Regeneron&#x27;s Dupixent picks up 9th FDA approval&lt;/a&gt;</a></h3>
        <p class="summary">In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for…</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-2026" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/pharma/immedica-cashes-after-fda-gives-ultra-rare-disease-drug-loargys-2nd-chance" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/pharma/immedica-cashes-after-fda-gives-ultra-rare-disease-drug-loargys-2nd-chance&quot; hreflang=&quot;en&quot;&gt;Immedica overcomes prior FDA rebuke for ultrarare disease med to score new approval&lt;/a&gt;</a></h3>
        <p class="summary">Four years after the FDA issued its most heavy-handed form of a rejection to pegzilarginase, the U.S. regulator has given the same treatment a thumbs-up. Scoring an accelerated nod is Immedica Pharma …</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/pharma/immedica-cashes-after-fda-gives-ultra-rare-disease-drug-loargys-2nd-chance" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/marketing/ardelyx-tees-lpga-tour-partnership-support-womens-digestive-health" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/marketing/ardelyx-tees-lpga-tour-partnership-support-womens-digestive-health&quot; hreflang=&quot;en&quot;&gt;Ardelyx tees up LPGA Tour partnership to support women&#x27;s digestive health&lt;/a&gt;</a></h3>
        <p class="summary">With a new corporate sponsorship in hand, Ardelyx is aiming for a hole-in-one in the awareness-raising game.</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/marketing/ardelyx-tees-lpga-tour-partnership-support-womens-digestive-health" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>

      <article class="article-card pipeline">
        <h3 class="title"><a href="https://www.fiercepharma.com/manufacturing/abbvie-us-investment-tear-splashes-380m-2-new-api-plants-illinois-home-campus" target="_blank" rel="noopener">&lt;a href=&quot;https://www.fiercepharma.com/manufacturing/abbvie-us-investment-tear-splashes-380m-2-new-api-plants-illinois-home-campus&quot; hreflang=&quot;en&quot;&gt;AbbVie advances US expansion with $380M for 2 new North Chicago API plants&lt;/a&gt;</a></h3>
        <p class="summary">The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company&#x27;s plan to infuse $100 billion into its American operations over the next …</p>
        <div class="meta">
          <span class="region region-us">US</span> <span class="importance"><span class="star">★</span><span class="star">★</span><span class="star empty">★</span><span class="star empty">★</span></span>
        </div>
        <div class="link-wrap"><a href="https://www.fiercepharma.com/manufacturing/abbvie-us-investment-tear-splashes-380m-2-new-api-plants-illinois-home-campus" target="_blank" rel="noopener">Fierce Pharma </a></div>
      </article>
    </section>

    <footer style="margin-top: 40px; padding-top: 20px; border-top: 1px solid var(--border); font-size: 0.75rem; color: var(--text-muted);">
      Pharma Daily Brief — PiercePharma 朝刊 | 米国中心・欧州大手・中国規制を含む医薬・バイオ業界の重要ニュース
    </footer>
  </div>
</body>
</html>